Liver

Liver Team

Fedja Rochling, MD

Dr. Rochling has been a member of the Gastroenterology and Hepatology team at the University of Nebraska Medical Center (UNMC) since 2002. He also serves an associate member of the Eppley Cancer Center and as a staff physician in Gastroenterology and Hepatology at the Veterans Administration Medical Center in Omaha, Nebraska.

Dr. Rochling sits on the Gastroenterology Fellowship Committee at UNMC along with the Hepatology Fellowship Committee and Consent Committee. He maintains active certification with the American Board of Internal Medicine in Gastroenterology, Transplant Hepatology and Internal Medicine. He is certified by the National Board of Nutrition Support Certification as a Nutrition Support Clinician.

Awards & Honors

  • 2005 - Top Teacher Award, UNMC Department of Internal Medicine

Research

  • Dr. Rochling spearheaded the Hepatocellular Carcinoma Work Group, incorporating specialties from several departments for a team approach in patient care and outcomes. He is the Collaborating Director of the Intestinal Rehabilitation Program. He has participated on several clinical trials of patients with liver disease and liver transplantation.

Completed Research Support

  • Rochling (PI): 07/01/05-12/31/06
    Bayer Corporation
    A Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Role: PI
  • Rochling (PI): 03/22/04-09/30/06
    Novartis Pharmaceuticals Corporation
    A 6-Week, Randomized, Double Blind, Placebo-Controlled, Multicenter Study, to Assess the Efficacy and Safety of Tegaserod (6 mg BID) and Placebo in Female Patients with Dyspepsia
    Role: PI
  • CHTF919B2203 Rochling (PI): 03/25/04-06/30/06
    Novartis Pharmaceuticals Corporation
    A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Tegaserod Alone and in Combination with Omeprazole Given Orally in Patients Suffering from Symptomatic (non-erosive) (cont.)
    Role: PI
  • CL0600-005 Gilroy (PI): 08/31/04-10/31/08
    PAREXEL International, LLC
    A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition (PN) Dependent Short Bowel Syndrome (SBS)
    Role: PI
  • CL0600-004 DiBaise (PI): 02/02/04-10/31/08
    PAREXEL International, LLC
    A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition (PN) Dependent Short Bowel Syndrome (SBS)
    Role: PI
  • Rochling (PI): 08/18/06-08/01/08
    Tioga Pharmaceuticals, Inc.
    A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of Asimadoline in Subjects with Irritable Bowel Syndrome
    Role: PI

Publications, Most Recent:

  • Rochling FA, Zetterman RK. Do hepatotoxicity registries have a role in health care? Gastroenterology 2008;135(6)1847-50
  • Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling FA, Van Hoek B, Majno P; Metroticket Investigator Study Group.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. Epub 2008 Dec
  • Rochling FA , Zetterman RK. Management of ascites. Drugs 2009.Vol 69,No 13 1739-1760
  • Compher C, Gilroy R, Pertkiewicz M, Ziegler T, Ratcliffe S, Joly F, Rochling F, Messing B. Patient outcomes of stopping teduglutide. Clin Nutr 2010; 5(S2): 8-9.
  • A 25-year experience with postresection short-bowel syndrome secondary to radiation therapy. Boland E, Thompson J, Rochling F Sudan D. Am J Surg. 2010 Dec;200(6):690-3
  • Current management of short bowel syndrome. Thompson JS, Weseman R, Rochling FA, Mercer DF. Surg Clin North Am. 2011 Jun;91(3):493-510.
  • Radiation therapy increases the risk of hepatobiliary complications in short bowel syndrome. Thompson JS, Weseman R, Rochling F, Grant W, Botha J, Langnas A, Mercer D. Nutr Clin Pract. 2011 Aug;26(4):474-8.
  • Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. Compher C, Gilroy R, Pertkiewicz M, Ziegler TR, Ratcliffe SJ, Joly F, Rochling F, Messing B. JPEN J Parenter Enteral Nutr. 2011 Sep;35(5):603-9.
  • In brief. Thompson JS, Rochling FA, Weseman RA, Mercer DF.Curr Probl Surg. 2012 Feb;49(2):46-50.
  • Current management of short bowel syndrome. Thompson JS, Rochling FA, Weseman RA, Mercer DF.Curr Probl Surg. 2012 Feb;49(2):52-115.
  • Preresection obesity increases the risk of hepatobiliary complications in short bowel syndrome. Thompson JS, Weseman RA, Rochling FA, Grant WJ, Botha JF, Langnas AN, Mercer DF. Nutrients 2012 Sept 26;4 (10): 1358-66
  • Acute Cholestatic Hepatitis A Virus Infection Presenting with Hemolytic Anemia and Renal Failure: A Case Report. European Journal of Gastroenterology & Hepatology 2013 Lapp T, Rochling FA

Professional Organization Memberships:

  • Gastroenterology Fellowship Committee, UNMC
  • Hepatology Fellowship Committee, UNMC
  • Consent Committee, UNMC
Refer a Patient